West Pharmaceutical Services, Inc. — FY2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019; filed February 21, 2020. The filing is an annual Form 10-K, with fourth-quarter data presented in the unaudited quarterly table. West designs and manufactures injectable-drug containment, packaging, delivery systems, analytical services and complex contract-manufactured devices. Operations are reported through Proprietary Products and Contract-Manufactured Products. International sales represented 55.7% of consolidated 2019 sales.
Financial performance and position
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Net sales | $1,839.9 million | $1,717.4 million | 7.1% increase |
| Gross profit | $605.7 million | $545.4 million | 11.1% increase |
| Gross margin | 32.9% | 31.8% | 1.1 percentage-point increase |
| Operating profit | $296.6 million | $240.3 million | 23.4% increase |
| Operating margin | 16.1% | 14.0% | 2.1 percentage-point increase |
| Net income | $241.7 million | $206.9 million | 16.8% increase |
| Diluted EPS | $3.21 | $2.74 | 17.2% increase |
| Operating cash flow | $367.2 million | $288.6 million | 27.2% increase |
Proprietary Products sales increased 6.9% to $1,398.6 million, while Contract-Manufactured Products sales increased 7.9% to $441.5 million. Excluding foreign-currency translation and acquisition-related sales, consolidated sales increased approximately 10.0%.
2019 fourth-quarter sales were $470.6 million, gross profit was $153.2 million, net income was $63.9 million and diluted EPS was $0.84, compared with fourth-quarter 2018 sales of $422.5 million, gross profit of $133.2 million, net income of $52.0 million and diluted EPS of $0.69.
At December 31, 2019, cash and cash equivalents were $439.1 million, working capital was $717.1 million, total debt was $257.3 million and equity was $1,573.2 million. The company had no borrowings under its $300.0 million revolving credit facility and reported $297.5 million of available borrowing capacity, including outstanding letters of credit.
Material changes versus the prior comparable period
- Growth was led by high-value components, ready-to-use seals, stoppers and plungers, NovaPure, Crystal Zenith, self-injection systems, FluroTec-coated components, and healthcare-related injection and diagnostic devices.
- Gross-margin expansion reflected favorable product mix, production efficiencies and price increases. SG&A increased 3.7%, while R&D expense decreased 3.5% to $38.9 million, partly because more development work was customer funded.
- Operating cash flow increased $78.6 million, but investing cash outflows increased to $228.0 million from $100.8 million, primarily because of the Daikyo investment, higher capital expenditures and the South Korea acquisition.
- West increased its ownership interest in Daikyo from 25% to 49% on November 1, 2019, for $85.1 million in cash and $4.9 million of treasury stock consideration.
- The company acquired its South Korean distributor in April 2019 for $18.9 million, recording $2.6 million of goodwill and an $11.2 million customer-relationships intangible asset.
- Total debt increased $61.2 million, primarily because of a new $90.0 million term loan. The company repaid borrowings under the revolving facility and remained in compliance with debt covenants.
- Proprietary Products backlog increased to $587.9 million at year-end from $407.3 million, with most of the 2019 backlog expected to be filled during 2020.
- The company completed its 2018 restructuring plan, which generated $4.9 million of 2019 charges and is expected to provide approximately $14.0 million of annualized savings.
Guidance, outlook, risks and unusual items
The filing does not provide a specific numerical 2020 earnings or sales outlook in the supplied text. Management stated that cash on hand, operating cash flow and revolver availability should be adequate for foreseeable liquidity needs and expected continued compliance with debt covenants during 2020.
- West issued a voluntary recall of its Vial2Bag product line in January 2019 because of potential unpredictable or variable dosing under certain conditions. The company recorded a net 2019 provision of $5.4 million for returns and related inventory and was continuing efforts to return the products to market.
- 2019 included $4.9 million of restructuring charges, a $1.9 million gain on fixed-asset sales, a $1.0 million Argentina currency-devaluation charge, a $3.5 million pension settlement charge, and a $4.7 million tax recovery related to previously paid international excise taxes.
- The 2019 effective tax rate was 20.2%, including a $10.3 million tax benefit from stock-based compensation and a $0.3 million benefit from federal law changes.
- Key risks include dependence on injectable therapies and customer drug launches, foreign-exchange exposure, pricing pressure, regulatory approval and compliance, product defects or recalls, manufacturing disruption, dependence on single-source suppliers, raw-material and energy costs, cybersecurity, healthcare-policy changes, LIBOR reform, and international political and economic conditions.
- Contractual obligations totaled $639.1 million, including $249.1 million of purchase obligations, $258.0 million of debt, $88.0 million of operating lease obligations and $37.4 million of interest on debt and interest-rate swaps.
- Unfunded pension and other postretirement obligations totaled approximately $50.4 million at year-end. Unrecognized tax benefits were $5.0 million, and the company had $214.2 million of undistributed foreign earnings treated as indefinitely reinvested without recorded withholding-tax provisions.
- The company adopted lease accounting guidance in 2019 and recorded operating lease right-of-use assets of $70.1 million and operating lease liabilities of $72.0 million at year-end. The filing states that the adoption did not materially affect the financial statements or internal controls.
Investor verification checklist
- Verify the sustainability of 2019 sales and margin growth after adjusting for foreign-currency translation, acquisitions, pricing and mix.
- Assess whether the $587.9 million Proprietary Products backlog converts to revenue and cash flow as expected during 2020.
- Monitor the Vial2Bag recall, remediation costs, regulatory status and timing of any product relaunch.
- Review Daikyo-related economics, including the increased 49% ownership, commercial agreements, purchases and royalty payments.
- Evaluate leverage, the $90.0 million floating-rate term loan, LIBOR transition exposure and debt maturities, particularly the $133.8 million due in 2024.
- Track international currency exposure, Argentina-related charges, supply-chain concentration and raw-material costs.
- Review tax-rate normalization, stock-based compensation tax benefits and the company’s permanent-reinvestment assertion for foreign earnings.
- Confirm that the company’s dividend and 2020 share-repurchase plans remain consistent with cash generation, capital expenditures and debt covenants.